AXSM logo

AXSM
Axsome Therapeutics Inc

11,806
Mkt Cap
$8.65B
Volume
279,398.00
52W High
$191.50
52W Low
$86.99
PE Ratio
-45.75
AXSM Fundamentals
Price
$172.23
Prev Close
$169.02
Open
$170.66
50D MA
$172.54
Beta
0.73
Avg. Volume
624,903.80
EPS (Annual)
-$3.68
P/B
97.40
Rev/Employee
$690,265.95
$8,981.00
Loading...
Loading...
News
all
press releases
Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda
(RTTNews) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor...
Nasdaq News: Markets·7h ago
News Placeholder
More News
News Placeholder
Hennion & Walsh Asset Management Inc. Cuts Stock Position in Axsome Therapeutics, Inc. $AXSM
Hennion & Walsh Asset Management Inc. cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 18.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,386 shares of the company's stock after selling 8,530 share...
MarketBeat·2d ago
News Placeholder
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·5d ago
News Placeholder
Axsome Therapeutics (NASDAQ:AXSM) Raised to Strong-Buy at Truist Financial
Truist Financial upgraded Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday...
MarketBeat·6d ago
News Placeholder
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·7d ago
News Placeholder
Guggenheim Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
Guggenheim increased their price objective on Axsome Therapeutics from $220.00 to $245.00 and gave the company a "buy" rating in a report on Wednesday...
MarketBeat·7d ago
News Placeholder
JPMorgan Chase & Co. Has $30.43 Million Holdings in Axsome Therapeutics, Inc. $AXSM
JPMorgan Chase & Co. boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 42.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,513 shares of the company's stock...
MarketBeat·9d ago
News Placeholder
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
Key PointsSuperstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter...
Nasdaq News: Markets·14d ago
News Placeholder
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has been given an average rating of "Moderate Buy" by the nineteen research firms that are covering the firm, Marketbeat.com reports. Two...
MarketBeat·16d ago
News Placeholder
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Eventide Asset Management LLC
Eventide Asset Management LLC raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.9% during the third quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·17d ago
<
1
2
...
>

Latest AXSM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.